Skip to main content
DOTZ NANO LIMITED logo

DOTZ NANO LIMITED — Investor Relations & Filings

Ticker · DTZ ISIN · AU000000DTZ4 LEI · 5299006IOOUPE3D4AY22 ASX Manufacturing
Open in API
Filings indexed 1,143 across all filing types
Latest filing 2021-05-04 Capital/Financing Update
Country AU Australia
Listing ASX DTZ

About DOTZ NANO LIMITED

https://dotz.tech/

Dotz Nano Limited is a technology company focused on the development and commercialization of advanced carbon-based materials. The company specializes in the synthesis of high-performance Graphene Quantum Dots (GQDs) and other carbon-based nanomaterials. Its core business activities include providing innovative solutions for anti-counterfeiting, brand protection, and product authentication through in-product tagging and tracing technologies. Dotz Nano's proprietary materials are utilized across diverse sectors, including oil and gas, chemicals, and electronics, to ensure supply chain integrity. Additionally, the company has expanded its portfolio to include advanced carbon-based sorbents designed for industrial carbon capture and environmental applications. By leveraging its expertise in nanotechnology, Dotz Nano aims to provide sustainable and scalable solutions for complex industrial challenges.

Recent filings

Filing Released Lang Actions
Proposed issue of Securities - DTZ 6 pages 30.6KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from DOTZ NANO LIMITED regarding a proposed issue of securities. It details the terms of a non pro rata offer of securities under a disclosure document or product disclosure statement (PDS), including the number of securities, offer price, timetable, and regulatory approvals. The content focuses on the company's capital raising activity and the issuance of new shares. There are no financial statements or detailed financial performance data, so it is not an Annual Report or Interim Report. It is not a report publication announcement since it contains substantive details about the proposed securities issue. This fits the definition of a Capital/Financing Update (CAP).
2021-05-04 English
Appendix 2A 18 pages 347.8KB
Regulatory Filings Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It details the issuance and quotation of securities such as options exercised, employee incentive scheme securities, and other convertible securities. The document is regulatory in nature, related to securities issuance and quotation, and does not contain financial statements or management discussion. It is not an annual report, earnings release, or any other financial report type. It is a formal regulatory filing to the exchange about securities quotation and issuance. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2021-05-04 English
Quarterly Report & Appendix 4C Cashflow Report - 31 March 21 10 pages 691.7KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'MARCH 2021 QUARTERLY REPORT' and includes detailed operational updates, business development progress, product testing, and financial information for the quarter ending 31 March 2021. It contains substantive financial data such as cash flow statements (Appendix 4C), cash balances, and operating cash flow items. The presence of detailed quarterly financial data and business commentary indicates this is a comprehensive interim financial report rather than a brief announcement or a regulatory filing. The document is approximately 15,000 characters long, which supports it being a full report rather than a short announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2021
2021-05-02 English
Appendix 3G 14 pages 1.3MB
Capital/Financing Update Classification · 95% confidence The document is an ASX and media release dated 3 May 2021 regarding the issue of unquoted options by Dotz Nano Limited. It includes detailed information about the issuance of unquoted options, references to Appendix 3B and Appendix 3G forms, and compliance with ASX listing rules. The content is focused on notifying the market about the issuance of new equity securities (unquoted options) and includes regulatory form details (Appendix 3G). There are no financial statements, earnings data, or management discussion of financial results. The document is an official announcement of a capital raising or equity issuance event, specifically the issuance of unquoted options, which fits the category of Capital/Financing Update (CAP).
2021-05-02 English
Dotz and Zohar Dalia Sign Supply and Distribution Agreements 4 pages 280.4KB
Capital/Financing Update Classification · 95% confidence The document is an ASX and media release dated 26 April 2021 announcing that Dotz Nano Limited has signed supply and distribution agreements with Zohar Dalia for an anti-viral disinfectant product. The text details the agreements, product features, pilot results, and market potential. There are no financial statements, quarterly or annual results, or regulatory filings such as certifications or voting results. The document is a corporate announcement about new commercial agreements and partnerships, not a financial report or regulatory filing. It fits best into the category of Capital/Financing Update (CAP) as it relates to business development and commercial agreements that could impact the company's capital or revenue prospects in the future.
2021-04-25 English
DTZ Completes Clinical Trial and Submits FDA EUA Application 3 pages 186.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX and media release dated 07 April 2021 from Dotz Nano Limited announcing the completion of a successful clinical trial and submission of an FDA Emergency Use Authorization (EUA) application for its SARS-CoV-2 virus detection technology. The content focuses on clinical trial results, regulatory application status, and potential future steps regarding FDA EUA. It is a public announcement of a regulatory and clinical milestone rather than a financial report, earnings release, or detailed investor presentation. There is no indication of financial data, management discussion, or detailed regulatory filings beyond the announcement itself. The document is approximately 6997 characters, which is relatively short and fits the profile of a regulatory announcement or media release. Given the nature of the content and the context, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance-related disclosures that do not fit other specific categories.
2021-04-06 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.